Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb ViiV Healthcare, the global specialist HIV company majority owned
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022Data reinforce ViiV Healthcare’s leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention London, 7 February 2022 – ViiV Healthca.
Data reinforce ViiV Healthcare's leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention ViiV Healthcare, the global specialist HIV company majority-owned
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV preventionGiven as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of H.